AngioDefender is the world’s first non-invasive device that successfully combines patent protected non-invasive sensor technology and a sophisticated software algorithm to quickly and cost effectively assesses Endothelial Cell Dysfunction (‘EDF’) and flow mediated dilation (‘FMD’) of the Brachial Artery (‘BA’).
The AngioDefender Testing System
The AngioDefender procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis. The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave data collected before and after BA occlusion by an upper arm sphygmomanometric cuff.
At the end of the AngioDefender testing procedure (~15 minutes), the maximal relative post-occlusion change in the diameter of the BA relative to baseline is calculated and expressed as a percentage of flow mediated dilation (‘%FMD). Based on independently conducted BAUI clinical study2 the following categories of ‘Risk of Cardiovascular Disease and Atherosclerosis’ relative to measured % FMD scores, are recommended:
AngioDefender CVD Risk Stratification
|% FMD Score||Risk of CVD & Atherosclerosis|
|< 6.0% FMD||High CVD Risk|
|6.1% to 9.9%||Moderate CVD Risk*|
|10.0% +||Low CVD Risk|
Note *: A score between 6.1% FMD to 7.4% FMD may be considered a ‘Higher’ Moderate Risk score. A score between 8.5% FMD to 9.9% FMD may be considered is a ‘Lower’ Moderate Risk score
AngioDefender reports 24 elements of the patient record and test parameters for each patient (illustrated below) including the ‘AngioDefender Cardiovascular Risk Score’, flow mediated dilation of the brachial artery (to assess endothelial cell function), maximum dilation of the brachial artery, time to maximum dilation, pulse rate, mean blood pressure, systolic and diastolic blood pressure and cuff pressure
Actual AngioDefender Test Report
May 16th, 2011
|Patient Name||Ms. YYYY XXXX||Patient Gender||Female|
|Patient DOB||October 23, 1980||Patient Age||30|
CVD Risk Score
|Patient Height||1 meter 57 cm||Patient Weight||51 Kg.|
|Yes; Father HTN,
|Patient Smoker||None||Patient Alcohol Consumption||None|
|Cuff Pressure||90||Occlusion Time||300 seconds|
AngioDefender is positioned to become a major aid to physicians in their diagnosis of early-stage cardiovascular disease in asymptomatic patients:
The AngioDefender system represents the most innovative solution to the technical, clinical, ease of use and cost challenges relating to assessment of endothelial dysfunction. These advantages position AngioDefender testing to become part of the standard screening methodology applied by physicians to their patients; as important part of helping physicians to assess early-stage cardiovascular disease and atherosclerosis particularly in asymptomatic patients. It is hoped that AngioDefender will help Physicians to diagnose early-stage CVD and atherosclerosis through:
AngioDefender represents an additional means of monitoring response to therapy and life-style modification, helping physicians to create personalized dosage and treatment regimens
Everist Genomics are developing mobile applications for AngioDefender to further enhance the clinical and economic value of the AngioDefender system. Smartphones, tablets & mobile applications enable healthcare professionals to access patient diagnostic and therapeutic information throughout the day and from any location. This improves quality of care and reduces the cost of patient care.